drugset / Trial / NCT00618826
A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer
Phase 2
Completed
14 enrolled
Barbara Ann Karmanos Cancer Institute
Eli Lilly and Company · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to look at a new chemotherapy schedule in metastatic breast cancer.
Timeline
- Start
- 2006-11
- Primary completion
- 2014-02
- Completion
- 2014-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1500 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | 150 mg | Intravenous |